文献速递血管炎

阿伐可泮治疗对ANCA相关性血管炎健康相关生活质量的影响:ADVOCATE试验数据的事后分析

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
PubMed 文献 · Lancet Rheumatol · 2023-07-24

该事后分析基于ADVOCATE试验(331例新诊断或复发性ANCA相关性血管炎患者),评估阿伐可泮对比泼尼松标准治疗对健康相关生活质量的影响。结果显示阿伐可泮组在26周和52周时生理成分总结评分及部分SF-36域显著优于泼尼松组,52周时EQ-5D和SF-6D健康效用评分也显著更优。

要点

  • 阿伐可泮组在26周和52周时生理成分总结评分较基线的改善显著大于泼尼松组。
  • 52周时阿伐可泮组EQ-5D视觉模拟量表、EQ-5D健康效用评分和SF-6D健康效用评分较基线的变化显著大于泼尼松组。
  • 阿伐可泮组至52周的中位泼尼松总用量约减少2500 mg。

核心结论

  • 接受阿伐可泮治疗的ANCA相关性血管炎患者在26周和52周时报告的健康相关生活质量改善具有统计学显著性和临床意义。
  • 52周时健康效用EQ-5D和SF-6D评分也显著改善。
  • 这些患者报告结局补充了研究者评估,支持阿伐可泮在使用较低泼尼松剂量的情况下对ANCA相关性血管炎患者的疗效。

研究设计与样本

  • 对ADVOCATE研究(NCT02994927)的患者报告结局数据进行事后分析,该研究为3期双盲双模拟随机对照试验。
  • 纳入新诊断或复发性ANCA相关性血管炎患者,在改良意向治疗人群中分析。
  • 使用SF-36版本2、EQ-5D-5L问卷和EQ-5D健康效用测量,在26周和52周评估预设健康相关生活质量结局的汇总评分和单个域评分。
  • 计算SF-6D评分作为额外的健康效用测量。

主要发现

  • ADVOCATE试验共纳入331例患者,阿伐可泮组166例,泼尼松标准治疗组165例。
  • 阿伐可泮组平均年龄61.2岁(SD 14.6),166例中男98例(59%)、女68例(41%),白人138例(83%);泼尼松组平均年龄60.5岁(14.5),164例中男88例(54%)、女76例(46%),白人140例(85%)。
  • 阿伐可泮组至52周的中位泼尼松总用量约减少2500 mg。
  • 生理成分总结评分较基线的最小二乘均值差异在26周和52周时阿伐可泮组显著大于泼尼松组,26周时8个SF-36域中的5个、52周时8个域中的2个也显著更优。
  • 报告评分等于或大于常模值的患者比例在所有SF-36域中26周和52周时阿伐可泮组均高于泼尼松组,但除26周时的角色生理和活力域外,差异无统计学显著性。

关键数值与推荐

  • 预设健康相关生活质量结局通过SF-36版本2、EQ-5D-5L和EQ-5D健康效用测量在26周和52周评估。
  • 评估了报告评分达到或超过健康相关生活质量最小临床重要差异的患者比例,并与匹配的美国健康人群年龄和性别特异性常模值比较。
  • 评估了报告评分达到或超过健康效用评分最小重要差异的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is characterised by inflammation and destruction of small to medium sized blood vessels. In the previously reported ADVOCATE study, a phase 3 double-blind, double-dummy randomised controlled trial of patients with newly diagnosed or relapsing ANCA-associated vasculitis, the oral selective complement 5a receptor inhibitor avacopan was shown to be non-inferior with regard to remission induction at week 26 and superior with regard to sustained remission at week 52, compared with a prednisone taper in a standard of care regimen. In this Article, we report an in-depth analysis of prespecified and exploratory patient-reported outcomes from the ADVOCATE study, measuring health-related quality of life and health utilities. METHODS: We did a post-hoc analysis of patient-reported outcome data from the ADVOCATE study (NCT02994927) of patients with newly diagnosed or relapsing ANCA-associated vasculitis. We analysed summary scores and individual domain scores for the prespecified health-related quality of life outcomes from ADVOCATE, which were evaluated at weeks 26 and 52 by use of the Medical Outcomes Survey 36-Item Short Form Health Survey (SF-36) version 2, the EuroQol 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L), and the EQ-5D health utility measure, assessed in the modified intention-to-treat population. We also calculated the Short Form 6 Dimension (SF-6D) score as an additional health utility measure. We evaluated the proportion of patients who reported scores that met or exceeded minimum clinically important differences in health-related quality of life, and we compared scores to normative values (age-specific and sex-specific scores from healthy populations from the USA matched to the protocol population). We also evaluated the proportion of patients who reported scores that met or exceeded minimum important difference in health utility scores. FINDINGS: 331 patients were enrolled in the ADVOCATE trial, of whom 166 were in the avacopan group and 165 were in the prednisone standard of care group. In the avacopan group, the mean age was 61·2 years (SD 14·6), 98 (59%) of 166 patients were men, 68 (41%) were women, and 138 (83%) were White; in the prednisone group, the mean age was 60·5 years (14·5), 88 (54%) of 164 patients were men, 76 (46%) were women, and 140 (85%) were White. Patients treated with avacopan received approximately 2500 mg less median total prednisone up to week 52. Least squares means difference from baseline in physical component summary scores were significantly greater in patients in the avacopan group compared with those in the prednisone group at weeks 26 and 52, as well as in five of eight SF-36 domains at week 26 and two of eight SF-36 domains at week 52. The proportion of patients reporting scores equal to or greater than normative values was higher in the avacopan group than in the prednisone group across all SF-36 domains at both week 26 and 52, although the differences were not statistically significant with the exception of the role physical and vitality domains at week 26. Least squares means change from baseline in EQ-5D-5L visual analogue scale, EQ-5D health utility scores, and SF-6D health utility scores were significantly greater at week 52 in the avacopan group compared with the prednisone group. INTERPRETATION: Patients with ANCA-associated vasculitis who received avacopan reported statistically significant and clinically meaningful improvements in health-related quality of life at 26 and 52 weeks and in health utility EQ-5D and SF-6D scores at 52 weeks. These patient-reported outcomes complement investigator assessments and support the efficacy of avacopan in patients with ANCA-associated vasculitis with use of lower prednisone doses. FUNDING: ChemoCentryx.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Strand V, Jayne DRW, Horomanski A, et al. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 2023. PMID: 38251577. doi:10.1016/S2665-9913(23)00092-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。